The U.S. Food and Drug Administration has expanded the approval of Sarepta Therapeutics' Elevidys (delandistrogene ...
The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for patients with ...
On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA will decide whether ...
The U.S. Food and Drug Administration has expanded its previous approval for Sarepta Therapeutics’ gene therapy to treat ...
The Food and Drug Administration on Thursday approved Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular ...
The U.S. FDA approved expanded use of Sarepta's gene therapy for Duchenne muscular dystrophy, spiking shares. A Texas judge ...
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted ...
The U.S. Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of ...
Shares of Sarepta SRPT rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.